Fig 1.

Enrollment. CONSORT diagram for the phase 1b/2 study-group patients treated with gene-mediated cytotoxic immunotherapy plus standard of care (GMCI + SOC) (left) and patients who received SOC therapy alone in the matched control cohort (right). Serious adverse events (SAEs) leading to mid-treatment dropout in the GMCI + SOC group were surgical complications and cardiac arrhythmia, deemed unlikely related to protocol treatment. Abbreviations: AdV-tk, aglatimagene besadenovec; SOC, standard of care; TMZ, temozolomide; XRT, radiation therapy.